• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.

作者信息

Haverkos Bradley, Zain Jasmine, Kamdar Manali, Neuwelt Alexander, Davila Eduardo, Bradeen Xander, Major Ajay, Bair Steven, Jasem Jagar, Smith Clayton, Abbott Diana, Porcu Pierluigi

机构信息

Division of Hematology, University of Colorado, Aurora, CO.

Division of Hematology, City of Hope, Duarte, CA.

出版信息

Blood Adv. 2024 Feb 13;8(3):708-711. doi: 10.1182/bloodadvances.2023011526.

DOI:10.1182/bloodadvances.2023011526
PMID:38150586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10845026/
Abstract
摘要

相似文献

1
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.纳武单抗与剂量调整的EPOCH方案一线化学免疫疗法治疗外周T细胞淋巴瘤：一项1期试验
Blood Adv. 2024 Feb 13;8(3):708-711. doi: 10.1182/bloodadvances.2023011526.
2
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.剂量调整的 EPOCH 化疗治疗未经治疗的外周 T 细胞淋巴瘤：西日本血液肿瘤组（West-JHOG）PTCL0707 的多中心 2 期试验。
Haematologica. 2017 Dec;102(12):2097-2103. doi: 10.3324/haematol.2017.167742. Epub 2017 Sep 29.
3
CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.长期纳武利尤单抗治疗晚期肺腺癌后患者出现 CD8 阳性外周 T 细胞淋巴瘤：一例报告。
Thorac Cancer. 2021 Jun;12(11):1765-1769. doi: 10.1111/1759-7714.13966. Epub 2021 May 3.
4
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.纳武利尤单抗治疗复发或难治性外周 T 细胞淋巴瘤患者：适度疗效和超进展病例。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004984.
5
[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].[采用EPOCH方案治疗的外周T细胞淋巴瘤（PTCL）患者的临床结局]
Ai Zheng. 2004 Aug;23(8):943-6.
6
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.依鲁替尼联合纳武单抗治疗复发非霍奇金淋巴瘤或慢性淋巴细胞白血病患者的安全性和活性：一项1/2a期研究
Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
7
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.抗CD2单克隆抗体西普利单抗联合DA-EPOCH-R方案用于侵袭性外周T细胞淋巴瘤的I期剂量递增研究。
Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16.
8
[A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].[1例顺铂联合吉西他滨加甲泼尼龙成功治疗的难治性肺外周T细胞淋巴瘤]
Nihon Kokyuki Gakkai Zasshi. 2010 Jan;48(1):28-32.
9
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.本妥昔单抗维特金治疗外周 T 细胞淋巴瘤和皮肤 T 细胞淋巴瘤。
Curr Hematol Malig Rep. 2020 Feb;15(1):9-19. doi: 10.1007/s11899-020-00561-w.
10
Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.抗CCR4抗体KW-0761用于成人T细胞白血病-淋巴瘤和外周T细胞淋巴瘤的I期研究剂量。
J Clin Oncol. 2010 Aug 10;28(23):e404-5; author reply e406. doi: 10.1200/JCO.2010.29.7242. Epub 2010 Jun 21.

引用本文的文献

1
Advances in classification and treatment of primary cutaneous lymphomas.原发性皮肤淋巴瘤的分类与治疗进展
Ann Hematol. 2025 Apr;104(4):2143-2157. doi: 10.1007/s00277-025-06311-3. Epub 2025 Mar 25.

本文引用的文献

1
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.纳武利尤单抗治疗复发或难治性外周 T 细胞淋巴瘤患者：适度疗效和超进展病例。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004984.
2
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.ECHELON-2 试验：brentuximab vedotin 联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤的随机 III 期研究的 5 年结果。
Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16.
3
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Geptanolimab (GB226) 治疗复发或难治性外周 T 细胞淋巴瘤的疗效和安全性：一项开放标签的 2 期研究（Gxplore-002）。
J Hematol Oncol. 2021 Jan 12;14(1):12. doi: 10.1186/s13045-021-01033-1.
4
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.抗 PD-1 阻断失败后复发难治性霍奇金淋巴瘤的化疗疗效。
Cancer Med. 2020 Nov;9(21):7830-7836. doi: 10.1002/cam4.3262. Epub 2020 Sep 2.
5
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.检查点阻断治疗可能使霍奇金淋巴瘤对后续治疗敏感。
Oncologist. 2020 Oct;25(10):878-885. doi: 10.1634/theoncologist.2020-0167. Epub 2020 Aug 28.
6
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.PD-1 抑制剂帕博利珠单抗治疗复发或难治性成熟 T 细胞淋巴瘤的 II 期研究。
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3.
7
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.剂量调整 EPOCH-R 与 R-CHOP 作为弥漫性大 B 细胞淋巴瘤一线治疗的比较：III 期联合组试验联盟/CALGB 50303 的临床结果。
J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.
8
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.联合免疫检查点抑制剂和化疗增强实体瘤的抗肿瘤反应。
Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.
9
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.抗程序性死亡蛋白1（PD-1）治疗失败后，化疗或化疗联合抗PD-1疗法用于复发难治性霍奇金淋巴瘤的疗效：来自Lysa中心的系列研究
Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
10
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.剂量调整的 EPOCH 化疗治疗未经治疗的外周 T 细胞淋巴瘤：西日本血液肿瘤组（West-JHOG）PTCL0707 的多中心 2 期试验。
Haematologica. 2017 Dec;102(12):2097-2103. doi: 10.3324/haematol.2017.167742. Epub 2017 Sep 29.